When a familiar 7-OH product disappears, a different name can arrive in its place: pseudo, MP, or mitragynine pseudoindoxyl. To a family, the new label may sound like a technical variation that does not change much. To the person using it, it may be presented as a replacement that delivers the desired effect without the ingredient attracting attention.
Neither interpretation is enough. Mitragynine pseudoindoxyl is a distinct opioid-active compound. A new name does not establish a safer product, an approved treatment, or an end to dependence. If someone is moving from one retail formulation to another because they become sick without it, the central concern is the pattern of use and the need for medical assessment.
This guide explains what is known, what remains uncertain, and how parents, partners, and adult children can respond. It is part of The Firm’s series on changing gas-station and smoke-shop products. Regulatory information was checked November 6, 2026.
Key Points
- Mitragynine pseudoindoxyl is not another spelling of mitragynine or 7-OH. Related names do not mean interchangeable products.
- Laboratory and preclinical findings identify opioid-receptor activity, but they do not establish a safe consumer regimen.
- It has appeared in the commercial market and in product testing; the available evidence does not establish nationwide usage rates.
- DEA temporarily placed mitragynine pseudoindoxyl in Schedule I effective August 26, 2026. Later proposed actions should not be confused with effective orders.
- Branding, a laboratory certificate, or a claim that a product is an alternative cannot establish safety for an individual.
- Dependence, combined substance use, and current symptoms matter more than winning a debate over the product’s name.
- Families can organize an assessment and a practical response without trying to manage withdrawal themselves.
Mitragynine Pseudoindoxyl at a Glance
| Question | What to understand |
|---|---|
| Names you may encounter | Mitragynine pseudoindoxyl, pseudo, or MP. Abbreviations alone are not reliable product identification. |
| Relationship to kratom | A kratom-related compound appearing in a market that includes concentrated and chemically modified alkaloid products. |
| Main concern | Opioid activity, dependence concerns, and substantial uncertainty about commercial formulations and human outcomes. |
| FDA-approved treatment? | No approved medical use was identified in the federal scheduling materials reviewed. |
| Federal status at review | Covered by the temporary Schedule I order effective August 26, 2026; legal details can change. |
| What families can document | Exact label, lot, recent use pattern, symptoms, other substances, and changes from earlier products. |
| What not to infer | A lower milligram number, a new formula, or a “tested” badge does not establish lower clinical risk. |
What Is Mitragynine Pseudoindoxyl?
Mitragynine pseudoindoxyl belongs to the broader discussion of kratom-related opioid compounds, but its name should not be shortened until important distinctions disappear. Mitragynine, 7-hydroxymitragynine, and mitragynine pseudoindoxyl are different substances. A package that mentions one does not automatically describe the others. The United Nations Office on Drugs and Crime has highlighted the emergence of concentrated 7-OH and related products, including pseudoindoxyl. (United Nations Office on Drugs and Crime [UNODC], 2025)
Research on opioid receptors can help explain why a compound deserves attention. It cannot, by itself, tell a family how a particular retail tablet will affect a particular person. Human health, other drugs, formulation, and the actual contents all matter. A scientific-sounding name may make the product feel well characterized even when important practical questions remain unanswered.
For the person using it, the distinction can feel abstract. They may say that it is simply the new version of something they have taken before. Ask what changed: the package, the seller’s description, how often they use, or how they feel between uses. That history gives clinicians a better starting point than treating every product in the sequence as the same substance.
Do not confuse an explanation of chemistry with an endorsement. Scientists can investigate a compound’s properties without establishing that a commercial version is an appropriate way to treat pain, distress, or withdrawal. Families should be particularly cautious when research language is used to support claims that a retail product is medically preferable.
Why “Stronger in a Study” Is Not a Consumer Safety Guide
Published preclinical work has examined mitragynine pseudoindoxyl’s opioid-receptor activity and related signaling. Those experiments contribute to drug research, but findings in cells or animals are not a clinical safety trial in people buying smoke-shop products. They do not establish a safe dose, a dependable comparison with another drug, or an appropriate home withdrawal strategy. (Váradi et al., 2016)
Potency claims often lose their context as they move from a paper to a product description or social-media post. A number may refer to one experimental endpoint, under particular conditions, rather than to real-world overdose risk. Comparing milligrams across different substances can create a false impression of precision. A small-looking number on a label is not reassurance.
Similarly, a discussion of a particular receptor-signaling pathway does not prove that a product cannot cause dependence or breathing problems. Families do not need to settle a technical pharmacology dispute to request care. A person who is repeatedly impaired, unable to stop, or organizing daily life around supply has a practical problem that deserves evaluation.
When someone presents a scientific article as proof that their product is safe, ask a narrower question: does the paper study this exact product in people under conditions resembling their use? If the answer is no, the paper may still be informative, but it cannot carry the conclusion being placed on it.
What the Evidence Can and Cannot Tell Families
| Evidence type | What it can establish | What it cannot establish |
|---|---|---|
| Receptor or animal research | Properties worth further scientific investigation. | A safe consumer regimen or a human overdose-risk percentage. |
| Testing of a submitted product | Results for the tested sample within the method’s scope. | The contents of every package bearing the same brand. |
| Regulatory assessment | The agency’s findings and the legal action described. | An individualized diagnosis or an estimate of local teenage use. |
| Broader kratom surveillance | A public-health signal across a broader product category. | A pseudoindoxyl-only prevalence or death count. |
| Family observations | Specific changes in behavior and functioning. | A chemical identification or a medical diagnosis. |
A public laboratory report for one Trance BARZ sample listed mitragynine pseudoindoxyl alongside 7-OH. That is a useful reminder that a product name and its most prominent ingredient may not tell the whole story. It is not evidence that all BARZ products contain the same combination. The report was issued for a specific submitted lot and states that sampling was not performed by the laboratory. (Anresco Laboratories, 2025)
We did not identify a reliable national estimate of pseudoindoxyl use among teenagers. It would be misleading to borrow numbers from a broader kratom study and label them as pseudoindoxyl statistics. A family can take a product seriously without needing an exaggerated count to justify concern.
Uncertainty should change how carefully claims are made, not whether serious symptoms receive attention. If a clinician does not initially recognize the product name, provide the label and explain the suspected compound. Ask whether toxicology or addiction-medicine consultation is appropriate rather than assuming unfamiliarity means there is nothing to do.
Current Federal Status and Why Dates Matter
DEA’s temporary order placed mitragynine pseudoindoxyl, MGM-15, and MGM-16 in Schedule I effective August 26, 2026. The order lists an end date of August 26, 2028 unless extended or made permanent. Its assessment identifies these as opioid-active substances without an accepted medical use in the United States. (Drug Enforcement Administration [DEA], 2026a)
A subsequent October 14, 2026 notice proposed another action involving 7-OH and mitragynine pseudoindoxyl. A proposed notice is not an immediately effective replacement for an existing order. As of this article’s review date, families should not read that later proposal as evidence that the August order had disappeared. Consult the current official record for legal questions. (DEA, 2026b)
For a family conversation, the legal status is relevant but not the only issue. A person may respond to a restriction by changing suppliers or products while the dependence remains. Focusing exclusively on whether a purchase was permitted can miss the more immediate questions: are they safe, can they stop, and what care is needed?
Pseudoindoxyl Compared With 7-OH and Other Alternatives
| Name | What the name represents | Common mistake to avoid |
|---|---|---|
| 7-OH | 7-hydroxymitragynine, a distinct opioid-active alkaloid. | Assuming every kratom-related product has the same composition. |
| Mitragynine pseudoindoxyl | A separate kratom-related opioid compound. | Assuming a new name means reduced dependence risk. |
| MGM-15 / MGM-16 | Other chemically distinct compounds discussed in the emerging market and federal actions. | Treating similar abbreviations as interchangeable ingredients. |
| Proprietary alternative blend | A manufacturer-defined formulation, not necessarily one chemical. | Reading total blend weight as the amount of one known active drug. |
Our 7-OH guide, MGM-15 and MGM-16 guide, and guide to alternative blends address those differences. The purpose of the comparison is identification and informed assessment, not choosing a substitute.
A family may hear, “At least I am not taking the old product anymore.” Acknowledge the change while asking whether the underlying problems have improved. Can the person attend work without repeated purchases? Can they travel without panic about supply? Have episodes of impairment stopped? Those questions bring the discussion back to functioning.
Recognizing a Cycle of Substitution and Dependence
Substitution can initially look like progress. The person throws away one packet, orders something with a different label, and says they have found a solution. If they are using the replacement to prevent sickness or keep functioning, however, the family still needs a professional assessment of dependence. The label change alone does not answer that question.
Listen for the practical constraints the person describes. They may be unable to leave the house before taking something, avoid situations where access is uncertain, or become distressed when a shipment is delayed. These are not proof of a particular diagnosis, but they identify the role the product has begun to play in daily life.
Ask about unsuccessful attempts to reduce use. What made the attempt difficult? Was there physical discomfort, fear, untreated pain, or pressure from work? The answers can help clinicians plan care and help relatives offer useful support. They should not be used to construct an improvised taper or to argue that the person simply lacks determination.
Record the sequence of products rather than only the latest one. Include approximate dates and any symptoms that appeared during switches. A concise timeline can reveal information that would otherwise be lost in an emotional conversation. It also reduces the pressure on the person to remember everything during an assessment.
Immediate Safety: Symptoms Before Product Arguments
Call 911 for unresponsiveness, slow or abnormal breathing, seizures, or another medical emergency. If opioid overdose is suspected, give available naloxone according to its instructions and follow emergency-dispatch guidance. Stay with the person and seek emergency care even if they seem to improve. (Centers for Disease Control and Prevention [CDC], n.d.)
Do not delay because you are unsure whether the package truly contains pseudoindoxyl. Responders need your observations and the available product information, not certainty you do not have. If you can safely provide the container, do so. Do not give another substance to reverse the effects or try to make the person vomit.
For a possible exposure without immediate life-threatening symptoms, call U.S. Poison Control at 1-800-222-1222. A child’s possible ingestion warrants prompt advice. Secure remaining products away from children and pets, and do not leave loose tablets mixed with ordinary household medication.
Alcohol, benzodiazepines, and other sedating substances are important to disclose. A person may not count a prescribed medication as part of their substance history, but clinicians need to know about it. Do not change established prescriptions on your own; ask the treating professional how to coordinate them safely.
How to Prepare for an Assessment
Bring a short written summary instead of a folder of alarming screenshots. Include the exact product names, the pattern of use, the last known use if available, previous attempts to stop, medical conditions, and all medications. Separate information you witnessed from information someone else reported. State clearly when the contents are uncertain.
Ask whether the provider can evaluate opioid-related dependence and whether specialist consultation is available. Also ask how the service handles urgent symptoms or an uncertain product formulation. A helpful answer should explain the next step and its limits rather than promise that one standard program fits everyone.
If a substance use disorder is diagnosed, treatment planning may include medication, counseling, and practical supports according to the person’s needs. Evidence-based medications for opioid use disorder exist, but this does not establish a one-size-fits-all regimen for pseudoindoxyl. A qualified clinician must assess the individual. (Substance Abuse and Mental Health Services Administration [SAMHSA], 2021)
Discuss barriers openly. Transportation, childcare, cost, work, fear of withdrawal, and previous negative treatment experiences can all affect follow-through. A family can help solve some of those problems while the clinician addresses medical care. Making the first appointment reachable is a concrete contribution.
Planning a Family Conversation That Leads Somewhere
Choose a time when the person can participate safely. Use a few specific observations: repeated spending, missed obligations, sickness when supply ends, or changes in alertness. Then make a clear offer of help. Avoid a lengthy lecture about every emerging compound; the immediate goal is assessment, not mastery of the marketplace.
An opening might be: “The products have changed, but you are still getting sick when you run out. We want to help you get medical advice and understand the options.” This language acknowledges the person’s experience while keeping the concern visible. It does not require them to agree to a label before accepting help.
Agree privately on boundaries before the conversation. One relative offering unlimited money while another threatens total cutoff can create confusion and conflict. Each person should decide what they can safely and consistently do. Boundaries work best when they describe your actions, such as offering transportation or paying a provider directly, rather than attempting to control every choice.
For a teenager, involve appropriate caregivers and adolescent professionals. For an adult, respect their decision-making while addressing risks to children, driving, or household safety. Do not recruit siblings to investigate or monitor use. They also need protection from the stress of the situation.
The Firm offers kratom and 7-OH intervention guidance and family coaching to help organize a response. Treatment placement guidance can help clarify options after appropriate assessment. These services do not replace emergency care or medical withdrawal management.
What to Record When Products Keep Changing
A family timeline is most useful when it is brief, factual, and dated. Start with the first product you know about, then record changes in the package or the person’s description. Include a photograph when available. Do not treat a guess about an ingredient as a confirmed fact; write “label says” or “person reports” where appropriate.
Next, record changes in functioning. Examples include missing an appointment, leaving work unexpectedly, being too impaired to drive safely, or becoming distressed when a supply ends. Avoid turning the document into a list of character judgments. The goal is to help an assessment, not to create a prosecution file.
Include the person’s own explanation. They may say that a change was intended to address cost, pain, unwanted effects, or difficulty stopping. That explanation helps clinicians understand the decision even if the family disagrees with it. A timeline that contains only relatives’ interpretations can miss information the person considers central.
Track attempts to seek help as well. Note appointments attended, referrals that could not be reached, and practical barriers. This distinguishes unwillingness from an incomplete or inaccessible care plan. It also prevents the next provider from repeating an approach that already failed for a clear reason.
Keep the record private and share it only with people appropriately involved in care. Do not post packages, names, or allegations about the person online in an effort to gather advice. Public exposure can damage trust while adding little useful clinical information. A direct conversation with a qualified professional is a better place for sensitive details.
For an adult, invite them to contribute and correct factual errors whenever the situation allows. For a young person, involve appropriate caregivers and professionals without asking siblings to collect evidence. The record should support a collaborative response rather than make the household feel like an investigation.
Bring the summary to the assessment along with questions you need answered. Ask what symptoms require urgent action, what follow-up is recommended, and whom to contact if the plan becomes difficult to carry out. Leave with a next step and a responsible contact rather than only a general instruction to watch the situation.
If the exact compound remains uncertain, preserve that uncertainty in subsequent conversations. A later assumption should not silently become a confirmed exposure in the family’s account. Accurate information remains valuable even when it is incomplete.
Frequently Asked Questions
Is pseudo the same as 7-OH?
No. Mitragynine pseudoindoxyl and 7-hydroxymitragynine are distinct compounds. Informal shorthand can obscure that difference, so share the exact label with the clinician.
Does a product being called an alternative mean it is safer?
No. “Alternative” is a comparison or marketing description. Safety requires evidence about the actual formulation and the individual, not simply the absence of one named ingredient.
Can a laboratory certificate prove a product is safe?
It can provide information about a tested sample and specified analyses. It does not establish clinical safety, verify every batch, or show that the product is appropriate for a particular person.
Do we know how many teenagers use pseudoindoxyl?
A reliable national teen-specific estimate was not identified for this article. Broader kratom statistics should not be presented as pseudoindoxyl prevalence.
Is it federally controlled?
As checked November 6, 2026, mitragynine pseudoindoxyl is covered by DEA’s temporary Schedule I order effective August 26, 2026. Consult current official sources for later changes and jurisdiction-specific questions.
Should a family replace it with ordinary kratom?
Do not design a replacement regimen from retail products or internet anecdotes. A clinician should assess dependence, current symptoms, other substances, and appropriate treatment.
What if the person refuses help?
Keep the offer specific, document concerns, and seek guidance for a coordinated family response. Maintain realistic boundaries and act immediately on medical emergencies rather than waiting for agreement about treatment.
Where can our family start?
Start with safety and an appropriate assessment. For help planning a conversation and coordinating next steps, contact The Firm or call 877-FIRM-910.
References
Anresco Laboratories. (2025, July 30). Report of analysis: Trance Barz 30 mg Blue Raspberry tablet (Sample 1323159). TestMyKratom.org. Laboratory report.
Centers for Disease Control and Prevention. (n.d.). About naloxone. Retrieved November 6, 2026, from CDC overdose prevention.
Drug Enforcement Administration. (2026a, August 26). Schedules of controlled substances: Temporary placement of mitragynine pseudoindoxyl, MGM-15, and MGM-16 in Schedule I. Federal Register, 91, 54948–54956. Temporary scheduling order.
Drug Enforcement Administration. (2026b, October 14). Schedules of controlled substances: Temporary placement of 7-hydroxymitragynine and mitragynine pseudoindoxyl in Schedule I [Notice of intent]. Federal Register notice.
Substance Abuse and Mental Health Services Administration. (2021). Medications for opioid use disorder (Treatment Improvement Protocol 63). Treatment guidance.
United Nations Office on Drugs and Crime. (2025, August 29). Emergence of products containing concentrated 7-hydroxymitragynine and related alkaloids [Early warning advisory]. Early warning information.
Váradi, A., Marrone, G. F., Palmer, T. C., Narayan, A., Szabó, M. R., Le Rouzic, V., Grinnell, S. G., Subrath, J. J., Warner, E., Kalra, S., Hunkele, A., Pagirsky, J., Eans, S. O., Medina, J. M., Xu, J., Pan, Y. X., Borics, A., Pasternak, G. W., McLaughlin, J. P., & Majumdar, S. (2016). Mitragynine/corynantheidine pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism, which do not recruit β-arrestin-2. Journal of Medicinal Chemistry, 59(18), 8381–8397. Research publication record.
Educational information, not individualized medical or legal advice. No commercial product is endorsed. The featured image is an editorial illustration, not a photograph of a person receiving care.

